In 2014, the skin substitute market will be significantly affected following the 2014 Hospital Outpatient Prospective Payment (HOPP) Final Rule especially when existing codes will expire for many major manufacturers in 2015.

US interactive dressings market composition

The U.S. Wound Management Market is expected to grow to over $10 billion by 2020. Growth will be driven by the introduction of new products that will be easier to use. However, this will be hindered by changes to reimbursement, specific to the U.S. interactive dressings market. The interactive dressings market is further segmented into collagen dressings and skin substitutes. The interactive dressings market experienced double digit growth in 2013 and the emergence of many new players in the market.

Interactive dressings market composition U.S. 2013

interactive dressings market compositon


“The skin substitutes market account for the majority of the interactive dressings market and will be significantly affected in the 2014 HOPP Final Rule, “says Dr. Kamran Zamanian, CEO of iData, “codes for many major manufacturers will expire in 2015.”

Revived interest in combination collagen dressings is expected to drive the collagen market. However, growth is expected to be hindered by the recent changes in the Pricing Data Analysis and Coding (PDAC) as well as Healthcare Common Procedure Coding System (HCPCS). This change has resulted in the removal of all collagen dressings which contain less than 90% of collagen from the collagen reimbursement codes.

Collagen Dressing Market, U.S., 2010 – 2020

Collagen Dressings Market	 to 2020

Competitors leading the U.S. interactive dressings market include Organogenesis with their Apligraf®,  Systagenix, Smith & Nephew, MiMedx,KCI and Osiris.

Organogenesis maintained their dominance in the market but other companies posted considerable increases in revenues from their products. Following Shire’s failure to receive FDA approval for treating venous leg ulcer with their Dermagraft® the company experienced significant decline in sales and revenue. In fact, their sales decreased so much that Organogenesis acquired the Dermagraft® product for free with a potential payment in the future depending on sales.

For more information

The U.S. Wound and Tissue Management Market report covers wound closure devices, static compression therapy, dynamic compression therapy, advanced dressings, hemostats, tissue sealants, anti-adhesion products and negative wound pressure therapy. The full reports provide a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success strategies in each market and segment

Get your free synopsis of the U.S. Wound and Tissue Management Market